Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Jeff Musgnung"'
Publikováno v:
Journal of Clinical Psychopharmacology. 34:365-368
The objective of this study was to determine whether the occurrence of discontinuation symptoms was equivalent for abrupt discontinuation versus 1-week taper to desvenlafaxine 25 mg/d after a 24-week treatment with desvenlafaxine 50 mg/d (administere
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::02dac9742f07f8dae646055adf264ebe
https://doi.org/10.1097/jcp.0000000000000100
https://doi.org/10.1097/jcp.0000000000000100
Publikováno v:
International Clinical Psychopharmacology. 28:312-321
This study assessed the efficacy of desvenlafaxine 50 mg/day compared with placebo for treating moderate or severe major depressive disorder (MDD). Data were pooled from six double-blind, placebo-controlled, desvenlafaxine 50 mg/day fixed-dose studie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ecc9c88486aeff04a4c7184c9cc59fbe
https://doi.org/10.1097/yic.0b013e3283638fbd
https://doi.org/10.1097/yic.0b013e3283638fbd
Publikováno v:
The Journal of Sexual Medicine. 10:768-776
Introduction. The symptoms of major depressive disorder (MDD) include sexual dysfunction, but antidepressant pharmacotherapies are also associated with treatment-emergent sexual dysfunction. Aim. These secondary and post hoc analyses evaluated sexual
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b865e71f183f9be3290982f301c84009
https://doi.org/10.1111/j.1743-6109.2012.02899.x
https://doi.org/10.1111/j.1743-6109.2012.02899.x
Autor:
Sujana Reddy, Philip T. Ninan, Bruno Pitrosky, Cecelia P. Kane, Jeff Musgnung, Christine J. Guico-Pabia
Publikováno v:
Current Medical Research and Opinion. 26:139-150
Major depressive disorder (MDD) is a common, seriously impairing illness. Desvenlafaxine (administered as desvenlafaxine succinate) is the third serotonin-norepinephrine reuptake inhibitor (SNRI) approved in the United States for the treatment of MDD
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::78ef7551f04a6a6d65f85f9d5c66b472
https://doi.org/10.1185/03007990903408678
https://doi.org/10.1185/03007990903408678
Autor:
Alan J. Gelenberg, Richard C. Shelton, Robert M. A. Hirschfeld, Martin B. Keller, Anthony J. Rothschild, James H. Kocsis, Jeff Musgnung, Philip T. Ninan, John Zajecka, Ronald Pedersen, Michael E. Thase, Alan F. Schatzberg, Charles B. Nemeroff, James M. Ferguson, David L. Dunner, Edward S. Friedman, Madhukar H. Trivedi, Susan G. Kornstein, Saeeduddin Ahmed, Bing Yan
Publikováno v:
The Journal of Clinical Psychiatry. 68:1246-1256
OBJECTIVE To report second-year results from the 2-year maintenance phase of a long-term study to evaluate the efficacy and safety of venlafaxine extended release (ER) in preventing recurrence of depression. METHOD Outpatients with recurrent unipolar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1de2528895223faa85c30d5c33efed10
https://doi.org/10.4088/jcp.v68n0812
https://doi.org/10.4088/jcp.v68n0812
Autor:
Alan F. Schatzberg, Richard C. Shelton, Robert M. A. Hirschfeld, Anthony J. Rothschild, Alan J. Gelenberg, James M. Ferguson, Michael E. Thase, Bing Yan, Madhukar H. Trivedi, James H. Kocsis, Ronald Pedersen, Saeeduddin Ahmed, Susan G. Kornstein, Jeff Musgnung, John Zajecka, David L. Dunner, Philip T. Ninan, Charles B. Nemeroff, Edward S. Friedman, Martin B. Keller
Publikováno v:
The Journal of Clinical Psychiatry. 68:1014-1023
OBJECTIVES To test the long-term efficacy and safety of venlafaxine extended-release (ER) in preventing recurrence in patients with major depression. METHOD This multiple-phase study, entitled "Prevention of Recurrent Episodes of Depression With Venl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9fd1f08bf8c326ffca58d7dc224dfd41
https://doi.org/10.4088/jcp.v68n0706
https://doi.org/10.4088/jcp.v68n0706
Autor:
Jeff Musgnung, Gina Buckley, Michael Messig, Tanya Ramey, Philip T. Ninan, Christine J. Guico-Pabia
Objective: The purpose of this post hoc analysis was to evaluate the incidence and timing of taper/posttherapy–emergent adverse events (TPAEs) following discontinuation of long-term treatment with desvenlafaxine (administered as desvenlafaxine succ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bdde5c1d7919de95d70ba7641e39cd6f
https://europepmc.org/articles/PMC4468885/
https://europepmc.org/articles/PMC4468885/
Autor:
I. Benattia, Phebe Tucker, Barbara O. Rothbaum, Gregory M. Asnis, Jonathan R. T. Davidson, Jeff Musgnung
Publikováno v:
Journal of Clinical Psychopharmacology. 26:259-267
This 12-week, double-blind, multicenter trial evaluated the efficacy of venlafaxine extended release (ER), sertraline, and placebo in adult outpatients (N = 538) with a primary diagnosis of posttraumatic stress disorder (PTSD), as defined in the Diag
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be1365bf3e49ee6a202071e8a2e6fa6c
https://doi.org/10.1097/01.jcp.0000222514.71390.c1
https://doi.org/10.1097/01.jcp.0000222514.71390.c1
Autor:
Philip T. Ninan, Christine J. Guico-Pabia, Boadie W. Dunlop, Rana Fayyad, Chuan-Chuan Wun, Jeff Musgnung, Michael E. Thase
Publikováno v:
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 37(13)
Variability in placebo response greatly complicates the design, conduct, and interpretation of clinical trials of antidepressant medications. To identify factors that impact detection of antidepressant–placebo differences, we conducted a meta-analy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18ff235b150e7815d0a590cecc14fc4a
https://pubmed.ncbi.nlm.nih.gov/22910458
https://pubmed.ncbi.nlm.nih.gov/22910458
Autor:
Jeff Musgnung, Anita H. Clayton, Philip T. Ninan, Susan G. Kornstein, Tanya Ramey, Boadie W. Dunlop, Weihang Bao, Kristen Focht
Publikováno v:
The Journal of clinical psychiatry. 74(10)
OBJECTIVE Evaluate the 8-week efficacy and safety of desvenlafaxine at the recommended dose of 50 mg/d in perimenopausal and postmenopausal women with major depressive disorder (MDD) based on the Diagnostic and Statistical Manual of Mental Disorders,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c49f2497c57bb792883108c8694b680d
https://pubmed.ncbi.nlm.nih.gov/24229754
https://pubmed.ncbi.nlm.nih.gov/24229754